How an eight-year partnership with Germer International helped Pharmaceutics International build the team behind its pivot from solid-dose manufacturing into sterile production — and a $309 million exit

Client Pharmaceutics International, Inc. (Pii)
Industry Contract Development and Manufacturing Organization (CDMO)
Partnership 2017–2025
Germer’s Focus Broad-based technical and leadership search — executive leadership, scientists, environmental and facilities/aseptic managers, and MS&T — supporting Pii’s expansion into sterile fill-finish and complex formulation
Placements 21 professionals, from the COO down to specialized technical and operations roles
Outcome Acquired by Jabil Inc. for $309 million 

THE CHALLENGE

Founded in 1994, Pii built its early reputation as a solid-dosage contract manufacturer, at a time when the CDMO industry itself was still young. As the market for outsourced pharmaceutical manufacturing matured, demand shifted toward more complex, higher-value capabilities — sterile fill-finish, high-potency compounds, and injectables. Pii needed to build both a workforce and a reputation to match, but the market — and candidates — still knew the company primarily for solid dose.

THE APPROACH

Germer International began working with Pii in 2017, filling the technical and leadership roles that had stalled when the company tried to fill them internally. “They would use us for the hard jobs — the ones that weren’t getting filled,” says John Germer, founder and CEO of Germer International. As with Kos and Qualitest, the work went beyond sourcing: Germer’s recruiters had to convince candidates that a company known for solid-dose manufacturing could credibly compete for sterile and complex-formulation talent, addressing the same underlying concerns — stability, growth trajectory, career risk — that come with joining a smaller, less recognized name.

The engagement also looked different from Germer’s work at Kos and Qualitest, which centered almost entirely on Quality Assurance. Building Pii’s sterile manufacturing capability required a broader bench: over eight years, Germer placed 21 professionals spanning the company’s Chief Operating Officer, scientists, environmental and facilities/aseptic managers, and Manufacturing Science & Technology (MS&T) roles. That mix reflects what it actually takes to convert a stated strategy — moving into sterile and complex manufacturing — into an operating reality: not just compliance talent, but the operational and scientific leadership to run it.

THE RESULT

Pii built the capabilities and market credibility to compete in sterile and complex manufacturing, culminating in its acquisition by Jabil Inc. in February 2025. While early reporting listed the deal as undisclosed, subsequent SEC filings placed the cash consideration at approximately $309 million — folding Pii’s drug product and clinical capabilities directly into Jabil’s healthcare and advanced device manufacturing division.

“That long-term commitment to find out what floats a candidate’s boat in a specific job is really, really critical. And you need to do it not just once, but many times, with the same job. That’s what people want to skip. That’s not how you build an organization.”

— John Germer, Founder & CEO, Germer International

* * *

Germer International specializes in executive and professional search for pharmaceutical, biotech, medical device, and nutraceutical companies. Germer International also partners with Private Equity and Venture investors in the space to help mitigate risk and find the best talent to spur growth and stability at their portfolio companies. To learn how Germer’s approach could support your next stage of growth, contact the firm today.